絞り込み

17061

広告

「"Chapuis AG "[Author]」の検索結果

21件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Prevalent and diverse intratumoral oncoprotein-specific CD8+ T cells within polyoma virus-driven Merkel cell carcinomas.

Age-Specific Incidence of Melanoma in the United States.

T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.

The response to lymphodepletion impacts PFS in aggressive non-Hodgkin lymphoma patients treated with CD19 CAR-T cells.

Immunotherapy for skin cancer.

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR-T cells.

Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA.

Merkel Cell Carcinoma: Current United States Incidence and Projected Increases based on Changing Demographics.

A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T cell function and therapy of murine leukemia.

Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8(+) T Cells In Vivo.

T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.

Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient.

T-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies.

New Strategies in Engineering T-cell Receptor Gene-Modified T Cells to More Effectively Target Malignancies.

Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I.

Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients.

Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype.

HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo.

Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.

  1. 1
  2. 2
Sort by
※並べ替えは表示に時間がかかります